Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709083 · ClinicalTrials.gov registry record · Phase 2
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02709083 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 7 participants.
The verdict
NCT02709083, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). Dasatinib, nilotinib, and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Dasatinib
- DRUG Nilotinib
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709083
The ClinicalTrials.gov registry entry for NCT02709083 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dasatinib is the first listed.
NCT02709083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709083 about?
NCT02709083 is a clinical study titled "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia". This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). Da...
What is the current status of trial NCT02709083?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-10. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02709083?
The interventions under investigation include: Dasatinib (DRUG), Nilotinib (DRUG), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT02709083?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.